{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:03:19Z","timestamp":1769108599251,"version":"3.49.0"},"reference-count":245,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Dementia with Lewy bodies (DLB) is one of the most common causes of dementia and belongs to the group of \u03b1-synucleinopathies. Due to its clinical overlap with other neurodegenerative disorders and its high clinical heterogeneity, the clinical differential diagnosis of DLB from other similar disorders is often difficult and it is frequently underdiagnosed. Moreover, its genetic etiology has been studied only recently due to the unavailability of large cohorts with a certain diagnosis and shows genetic heterogeneity with a rare contribution of pathogenic mutations and relatively common risk factors. The rapid increase in the reported cases of DLB highlights the need for an easy, efficient and accurate diagnosis of the disease in its initial stages in order to halt or delay the progression. The currently used diagnostic methods proposed by the International DLB consortium rely on a list of criteria that comprises both clinical observations and the use of biomarkers. Herein, we summarize the up-to-now reported knowledge on the genetic architecture of DLB and discuss the use of prodromal biomarkers as well as recent promising candidates from alternative body fluids and new imaging techniques.<\/jats:p>","DOI":"10.3390\/ijms22083960","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T05:52:00Z","timestamp":1618206720000},"page":"3960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-6078","authenticated-orcid":false,"given":"Romina","family":"Combi","sequence":"first","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Salsone","sequence":"additional","affiliation":[{"name":"Institute of Molecular Bioimaging and Physiology, National Research Council, 20054 Segrate (MI), Italy"},{"name":"Department of Clinical Neurosciences, Neurology-Sleep Disorder Center, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-5974","authenticated-orcid":false,"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Ferini-Strambi","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, Neurology-Sleep Disorder Center, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy"},{"name":"Department of Clinical Neurosciences, \u201cVita-Salute\u201d San Raffaele University, 20127 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/cjn.2016.2","article-title":"The Prevalence and Incidence of Dementia with Lewy Bodies: A Systematic Review","volume":"43","author":"Hogan","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS562>3.0.CO;2-3","article-title":"Dementia with Lewy bodies: Diagnosis and management","volume":"16","author":"Barber","year":"2001","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","article-title":"The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies","volume":"14","author":"Ferman","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","article-title":"The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies","volume":"44","year":"2014","journal-title":"Psychol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00441-017-2733-6","article-title":"Propagation of alpha-synuclein pathology from the olfactory bulb: Possible role in the pathogenesis of dementia with Lewy bodies","volume":"373","author":"Cersosimo","year":"2018","journal-title":"Cell Tissue Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson\u2019s disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/2051-5960-1-65","article-title":"Clinical and multimodal biomarker correlates of ADNI neuropathological findings","volume":"1","author":"Toledo","year":"2013","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.40.1.1","article-title":"The Lewy body variant of Alzheimer\u2019s disease: A clinical and pathologic entity","volume":"40","author":"Hansen","year":"1990","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","article-title":"Clinical prevalence of Lewy body dementia","volume":"10","author":"Kane","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archneurol.2010.319","article-title":"Familial aggregation of dementia with Lewy bodies","volume":"68","author":"Nervi","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11910-018-0874-y","article-title":"The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions","volume":"18","author":"Orme","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","article-title":"Investigating the genetic architecture of dementia with Lewy bodies: A two-stage genome-wide association study","volume":"17","author":"Guerreiro","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nbd.2019.04.004","article-title":"Heritability and genetic variance of dementia with Lewy bodies","volume":"127","author":"Guerreiro","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jnnp.2008.151654","article-title":"Twin pairs discordant for neuropathologically confirmed Lewy body dementia","volume":"80","author":"Wang","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-3940(94)90190-2","article-title":"Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer\u2019s disease","volume":"182","author":"Hardy","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","article-title":"Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies","volume":"23","author":"Bras","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40478-020-0879-z","article-title":"Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies","volume":"8","author":"Orme","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/jnc.13570","article-title":"The contribution of alpha synuclein to neuronal survival and function\u2014Implications for Parkinson\u2019s disease","volume":"137","author":"Benskey","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jocn.2005.11.040","article-title":"Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation","volume":"13","author":"Morfis","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.410400513","article-title":"Clinical genetic analysis of Parkinson\u2019s disease in the Contursi kindred","volume":"40","author":"Golbe","year":"1996","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-008-0372-4","article-title":"Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson\u2019s disease. Variability in familial Parkinson\u2019s disease","volume":"116","author":"Markopoulou","year":"2008","journal-title":"Acta Neuropathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ana.24664","article-title":"\u03b1-synuclein genetic variability: A biomarker for dementia in Parkinson disease","volume":"79","author":"Guella","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/gps.5260","article-title":"Systematic review of genetic association studies in people with Lewy body dementia","volume":"35","author":"Sanghvi","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/01.WNL.0000139870.14385.3C","article-title":"Beta-synuclein gene alterations in dementia with Lewy bodies","volume":"63","author":"Ohtake","year":"2004","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/archneurol.2010.177","article-title":"Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease","volume":"67","author":"Nishioka","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Davis, A.A., Inman, C.E., Wargel, Z.M., Dube, U., Freeberg, B.M., Galluppi, A., Haines, J.N., Dhavale, D.D., Miller, R., and Choudhury, F.A. (2020). genotype regulates pathology and disease progression in synucleinopathy. Sci. Transl. Med., 12.","DOI":"10.1126\/scitranslmed.aay3069"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhao, N., Attrebi, O.N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y.A., Meneses, A.D., Li, F., Shue, F., and Zheng, J. (2020). APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid. Sci. Transl. Med., 12.","DOI":"10.1126\/scitranslmed.aay1809"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/jnnp-2013-307228","article-title":"Apolipoprotein E \u03b52 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort","volume":"85","author":"Berge","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3182a2cbd1","article-title":"Risk factors for dementia with Lewy bodies: A case-control study","volume":"81","author":"Boot","year":"2013","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.JGP.0000225088.29353.08","article-title":"APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: Investigating genotype-phenotype effect on disease risk","volume":"14","author":"Borroni","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1212\/WNL.50.2.388","article-title":"Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer\u2019s disease and in dementia with Lewy bodies. Distinctions between diseases","volume":"50","author":"Lamb","year":"1998","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Larsson, V., Torisson, G., and Londos, E. (2018). Relative survival in patients with dementia with Lewy bodies and Parkinson\u2019s disease dementia. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202044"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nbd.2016.06.004","article-title":"Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies","volume":"94","author":"Geiger","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archneurol.2009.54","article-title":"Association of glucocerebrosidase mutations with dementia with lewy bodies","volume":"66","author":"Clark","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaneurol.2016.1593","article-title":"High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews","volume":"73","author":"Shiner","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1212\/01.wnl.0000230215.41296.18","article-title":"Glucocerebrosidase mutations are an important risk factor for Lewy body disorders","volume":"67","author":"Giasson","year":"2006","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneurol.2007.68","article-title":"Glucocerebrosidase gene mutations: A risk factor for Lewy body disorders","volume":"65","author":"Mata","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","article-title":"GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology","volume":"79","author":"Tsuang","year":"2012","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1038\/tp.2015.220","article-title":"Exome sequencing in dementia with Lewy bodies","volume":"6","author":"Keogh","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ana.20393","article-title":"A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer\u2019s disease","volume":"57","author":"Ishikawa","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"629.e5","DOI":"10.1016\/j.neurobiolaging.2011.10.014","article-title":"DLB and PDD: A role for mutations in dementia and Parkinson disease genes?","volume":"33","author":"Meeus","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.07.009","article-title":"An update on the genetics of dementia with Lewy bodies","volume":"43","author":"Vergouw","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1097\/00001756-199711100-00042","article-title":"No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies","volume":"8","author":"Singleton","year":"1997","journal-title":"Neuroreport"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0000000000001946","article-title":"Role for the microtubule-associated protein tau variant p.A152T in risk of \u03b1-synucleinopathies","volume":"85","author":"Ogaki","year":"2015","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jalz.2016.05.002","article-title":"MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies","volume":"12","author":"Heckman","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.neurobiolaging.2012.06.015","article-title":"MAPT H1 haplotype is associated with enhanced \u03b1-synuclein deposition in dementia with Lewy bodies","volume":"34","author":"Gelpi","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_55","first-page":"359","article-title":"Dementia risk in Parkinson disease: Disentangling the role of MAPT haplotypes","volume":"68","author":"Pagonabarraga","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1212\/01.wnl.0000339400.64213.56","article-title":"Intrafamilial diversity of phenotype associated with app duplication","volume":"71","author":"Berger","year":"2008","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1440-1789.2005.00605.x","article-title":"Overlap between neurodegenerative disorders","volume":"25","author":"Armstrong","year":"2005","journal-title":"Neuropathology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s004019900155","article-title":"Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation","volume":"100","author":"Rosenberg","year":"2000","journal-title":"Acta Neuropathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1212\/01.wnl.0000310643.53587.87","article-title":"A novel PSEN2 mutation associated with a peculiar phenotype","volume":"70","author":"Piscopo","year":"2008","journal-title":"Neurology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00401-005-1042-4","article-title":"Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene","volume":"110","author":"Yamaguchi","year":"2005","journal-title":"Acta Neuropathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.neurobiolaging.2018.10.019","article-title":"A comprehensive screening of copy number variability in dementia with Lewy bodies","volume":"75","author":"Orme","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1038\/s41598-019-43458-2","article-title":"GBA and APOE \u03b54 associate with sporadic dementia with Lewy bodies in European genome wide association study","volume":"9","author":"Rongve","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3233\/JAD-150750","article-title":"Association of Butyrylcholinesterase-K Allele and Apolipoprotein E \u025b4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer\u2019s Disease","volume":"50","author":"Vijayaraghavan","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000230036","article-title":"Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia","volume":"28","author":"Csibri","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13554794.2019.1601230","article-title":"CSF1R mutation presenting as dementia with Lewy bodies","volume":"25","author":"Sharma","year":"2019","journal-title":"Neurocase"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1101\/gr.210609.116","article-title":"Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource","volume":"27","author":"Keogh","year":"2017","journal-title":"Genome Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(18)30179-0","article-title":"LRP10 genetic variants in familial Parkinson\u2019s disease and dementia with Lewy bodies: A genome-wide linkage and sequencing study","volume":"17","author":"Quadri","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2016.07.015","article-title":"LRRK2 variation and dementia with Lewy bodies","volume":"31","author":"Heckman","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.55.2.302","article-title":"Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies","volume":"55","author":"Chinnery","year":"2000","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00001756-200002070-00015","article-title":"The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies","volume":"11","author":"Xu","year":"2000","journal-title":"Neuroreport"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/01.WNL.0000033796.33205.B4","article-title":"A patient with dementia with Lewy bodies and codon 232 mutation of PRNP","volume":"59","author":"Koide","year":"2002","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0891988702250585","article-title":"Familial dementia with Lewy bodies with an atypical clinical presentation","volume":"16","author":"Bonner","year":"2003","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.parkreldis.2019.02.011","article-title":"Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob\u2019s disease","volume":"63","author":"Geut","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00401-012-1059-4","article-title":"Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia","volume":"125","author":"Fujioka","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1093\/brain\/awr294","article-title":"Prion protein gene M232R variation is probably an uncommon polymorphism rather than a pathogenic mutation","volume":"135","author":"Beck","year":"2012","journal-title":"Brain"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00401-019-02026-8","article-title":"A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer\u2019s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity","volume":"138","author":"Conway","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrg3270","article-title":"DNA methylation profiling in the clinic: Applications and challenges","volume":"13","author":"Heyn","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pcn.12462","article-title":"DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies","volume":"71","author":"Funahashi","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3233\/JAD-143060","article-title":"The APOE Gene is Differentially Methylated in Alzheimer\u2019s Disease","volume":"48","author":"Foraker","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jalz.2018.02.005","article-title":"APOE DNA methylation is altered in Lewy body dementia","volume":"14","author":"Tulloch","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ane.13186","article-title":"DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson\u2019s disease","volume":"141","author":"Ozaki","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mp.2016.242","article-title":"Opening up the DNA methylome of dementia","volume":"22","author":"Esteller","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1038\/tp.2015.214","article-title":"Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns","volume":"6","author":"Heyn","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1074\/jbc.C110.212589","article-title":"Alpha-synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases","volume":"286","author":"Desplats","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Villa, C., Lavitrano, M., Salvatore, E., and Combi, R. (2020). Molecular and Imaging Biomarkers in Alzheimer\u2019s Disease: A Focus on Recent Insights. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030061"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal Fluid Alzheimer\u2019s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort","volume":"54","author":"Aarsland","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","article-title":"Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with dementia and dementia with Lewy bodies","volume":"64","author":"Parnetti","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid-beta-peptides in Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bellomo, G., Paolini Paoletti, F., Chipi, E., Petricciuolo, M., Simoni, S., Tambasco, N., and Parnetti, L. (2020). A\/T\/(N) Profile in Cerebrospinal Fluid of Parkinson\u2019s Disease with\/without Cognitive Impairment and Dementia with Lewy Bodies. Diagnostics, 10.","DOI":"10.3390\/diagnostics10121015"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","article-title":"Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer\u2019s disease and dementia with Lewy bodies","volume":"44","author":"Vanderstichele","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","article-title":"Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"81","author":"Kasuga","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","article-title":"Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage","volume":"89","author":"Bousiges","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer\u2019s disease from non-Alzheimer\u2019s dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-141986","article-title":"Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-\u03b2 Isoforms for Early and Differential Dementia Diagnosis","volume":"45","author":"Struyfs","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.199398","article-title":"CSF amyloid \u03b238 as a novel diagnostic marker for dementia with Lewy bodies","volume":"82","author":"Mulugeta","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2009-0955","article-title":"Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders","volume":"16","author":"Spies","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","article-title":"Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia","volume":"9","author":"Chiasserini","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kapaki, E., Paraskevas, G.P., Emmanouilidou, E., and Vekrellis, K. (2013). The diagnostic value of CSF \u03b1-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081654"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00702-019-02137-2","article-title":"High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases","volume":"127","author":"Bougea","year":"2020","journal-title":"J. Neural. Transm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00415-016-8259-0","article-title":"Cerebrospinal \u03b1-synuclein in \u03b1-synuclein aggregation disorders: Tau\/\u03b1-synuclein ratio as potential biomarker for dementia with Lewy bodies","volume":"263","author":"Llorens","year":"2016","journal-title":"J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"\u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies","volume":"33","author":"Majbour","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2018.00415","article-title":"Are We Ready for Detecting \u03b1-Synuclein Prone to Aggregation in Patients? The Case of \u201cProtein-Misfolding Cyclic Amplification\u201d and \u201cReal-Time Quaking-Induced Conversion\u201d as Diagnostic Tools","volume":"9","author":"Paciotti","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","article-title":"Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo","volume":"74","author":"Klein","year":"2010","journal-title":"Neurology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-014-0090-1","article-title":"The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer\u2019s disease","volume":"7","author":"Vermeiren","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3233\/JAD-2011-110482","article-title":"CSF tau, A\u03b242, and MHPG differentiate dementia with Lewy bodies from Alzheimer\u2019s disease","volume":"27","author":"Aerts","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jalz.2013.05.1775","article-title":"Addition of MHPG to Alzheimer\u2019s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease but not other dementias","volume":"10","author":"Herbert","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","article-title":"Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer\u2019s disease and dementia with Lewy bodies","volume":"26","author":"Szot","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_108","first-page":"172","article-title":"Cerebrospinal fluid and serum MHPG improve Alzheimer\u2019s disease versus dementia with Lewy bodies differential diagnosis","volume":"10","author":"Janssens","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.3232","article-title":"The role of autophagy in neurodegenerative disease","volume":"19","author":"Nixon","year":"2013","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.nbd.2009.03.002","article-title":"Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies","volume":"34","author":"Parnetti","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2217\/fnl-2018-0003","article-title":"Role of FABP3 as biomarker in Alzheimer\u2019s disease and synucleinopathies","volume":"13","author":"Sepe","year":"2018","journal-title":"Future Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-020-00388-2","article-title":"Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: A proteomic approach","volume":"15","author":"Vergouw","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000329763","article-title":"Decreased \u03b1-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer\u2019s disease patients and control subjects","volume":"31","author":"Laske","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease","volume":"20","author":"Salem","year":"2006","journal-title":"FASEB J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3233\/JAD-190567","article-title":"Erythrocytes as Biomarkers for Dementia: Analysis of Protein Content and Alpha-Synuclein","volume":"71","author":"Graham","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Marsal-Garc\u00eda, L., Urbizu, A., Arnaldo, L., Campdelacreu, J., Vilas, D., Ispierto, L., Gasc\u00f3n-Bayarri, J., Re\u00f1\u00e9, R., \u00c1lvarez, R., and Beyer, K. (2021). Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020725"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0165-1781(94)90046-9","article-title":"CSF and plasma MHPG, and CSF MHPG index: Pretreatment levels in diagnostic groups and response to somatic treatments","volume":"51","author":"Sharma","year":"1994","journal-title":"Psychiatry Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JPD-171228","article-title":"Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease","volume":"8","author":"Vermeiren","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"32679","DOI":"10.1074\/jbc.R110.135210","article-title":"Tissue-specific functions in the fatty acid-binding protein family","volume":"285","author":"Storch","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2004.07.061","article-title":"Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases","volume":"370","author":"Steinacker","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000105157","article-title":"Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies","volume":"4","author":"Mollenhauer","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/2211536607666180827111633","article-title":"MiRNAs: Biology, Biogenesis, their Web-based Tools, and Databases","volume":"8","author":"Tafrihi","year":"2019","journal-title":"Microrna"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1254\/jphs.10R11FM","article-title":"MicroRNAs and their therapeutic potential for human diseases: Aberrant microRNA expression in Alzheimer\u2019s disease brains","volume":"114","author":"Satoh","year":"2010","journal-title":"J. Pharmacol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/JAD-2008-14103","article-title":"Identification of miRNA changes in Alzheimer\u2019s disease brain and CSF yields putative biomarkers and insights into disease pathways","volume":"14","author":"Cogswell","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fnins.2018.00625","article-title":"Circulating miRNAs as Diagnostic Biomarkers for Parkinson\u2019s Disease","volume":"12","author":"Roser","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"585432","DOI":"10.3389\/fnins.2020.585432","article-title":"microRNA-Based Biomarkers in Alzheimer\u2019s Disease (AD)","volume":"14","author":"Zhao","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"101732","DOI":"10.1016\/j.pneurobio.2019.101732","article-title":"Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders","volume":"185","author":"Krauskopf","year":"2020","journal-title":"Prog. Neurobiol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Shigemizu, D., Akiyama, S., Asanomi, Y., Boroevich, K.A., Sharma, A., Tsunoda, T., Sakurai, T., Ozaki, K., Ochiya, T., and Niida, S. (2019). A comparison of machine learning classifiers for dementia with Lewy bodies using miRNA expression data. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0607-3"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1750-3639.2011.00530.x","article-title":"A-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson\u2019s disease","volume":"22","author":"Yakunin","year":"2012","journal-title":"Brain Pathol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"G\u00e1mez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Samaniego, D., Gasc\u00f3n-Bayarri, J., Re\u00f1\u00e9, R., \u00c1lvarez, R., Armengol, M.P., and Borr\u00e0s, F.E. (2020). Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease. bioaRxiv.","DOI":"10.1101\/2020.05.04.075713"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.bbrc.2016.09.114","article-title":"Gene expression profiling of brain samples from patients with Lewy body dementia","volume":"479","author":"Pietrzak","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.brainres.2017.11.009","article-title":"MicroRNA expression patterns in human anterior cingulate and motor cortex: A study of dementia with Lewy bodies cases and controls","volume":"1678","author":"Nelson","year":"2018","journal-title":"Brain Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.mcn.2010.11.004","article-title":"Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity","volume":"46","author":"Lachenal","year":"2011","journal-title":"Mol. Cell Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.13635","article-title":"DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients","volume":"8","author":"Alonso","year":"2017","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s12035-013-8544-1","article-title":"Exosomes: Mediators of neurodegeneration, neuroprotection and therapeutics","volume":"49","author":"Kalani","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"37043","DOI":"10.18632\/oncotarget.6158","article-title":"Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease","volume":"6","author":"Gui","year":"2015","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-161179","article-title":"MicroRNA Profile in Patients with Alzheimer\u2019s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples","volume":"57","author":"Riancho","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40035-019-0169-5","article-title":"Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer\u2019s disease and dementia with Lewy bodies","volume":"8","author":"Campdelacreu","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1007\/s12035-018-1032-x","article-title":"MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer\u2019s Disease","volume":"55","author":"McKeever","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., and Villa, S. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer\u2019s and Parkinson\u2019s diseases correlate with disease status and features of pathology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094839"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-016-0053-5","article-title":"miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer\u2019s disease and other types of dementia\u2014An exploratory study","volume":"5","author":"Nygaard","year":"2016","journal-title":"Transl. Neurodegener."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"580199","DOI":"10.3389\/fnagi.2020.580199","article-title":"Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia","volume":"12","author":"Dong","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","article-title":"A new potential biomarker for dementia with Lewy bodies: Skin nerve \u03b1-synuclein deposits","volume":"89","author":"Donadio","year":"2017","journal-title":"Neurology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10286-018-0581-4","article-title":"Skin nerve \u03b1-synuclein deposits in Parkinson\u2019s disease and other synucleinopathies: A review","volume":"29","author":"Donadio","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/mds.28242","article-title":"Blinded RT-QuIC Analysis of \u03b1-Synuclein Biomarker in Skin Tissue From Parkinson\u2019s Disease Patients","volume":"35","author":"Manne","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin \u03b1-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1212\/01.wnl.0000436942.55281.47","article-title":"Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies","volume":"81","author":"Ferman","year":"2013","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3233\/JAD-150138","article-title":"The Synergistic Relationship between Alzheimer\u2019s Disease and Sleep Disorders: An Update","volume":"46","author":"Villa","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.sleep.2013.02.016","article-title":"Rapid eye movement sleep behavior disorder: Devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group","volume":"14","author":"Schenck","year":"2013","journal-title":"Sleep Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrneurol.2017.157","article-title":"Idiopathic REM sleep behaviour disorder and neurodegeneration\u2014An update","volume":"14","author":"Stefani","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(13)70056-5","article-title":"Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study","volume":"12","author":"Iranzo","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","article-title":"The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies","volume":"43","author":"Galbiati","year":"2019","journal-title":"Sleep Med. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: A longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurology."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ana.25239","article-title":"How does dementia with Lewy bodies start? prodromal cognitive changes in REM sleep behavior disorder","volume":"83","author":"Postuma","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14737175.2019.1640603","article-title":"Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder","volume":"19","author":"Fasiello","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1017\/S1041610216000156","article-title":"In vivo imaging of neurodegeneration in dementia with Lewy bodies (DLB)","volume":"28","author":"Onyike","year":"2016","journal-title":"Int. Psychogeriatr."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1532-5415.2011.03379.x","article-title":"Combined use of cardiac m-i123-iodobenzylguanidine scintigraphy and \u00b923I-fp-cit single photon emission computed tomography in older adults with rapid eye movement sleep behavior disorder","volume":"59","author":"Labate","year":"2011","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.irn.2018.10.007","article-title":"Molecular Imaging of Dementia With Lewy Bodies","volume":"144","author":"Cousins","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/mds.26547","article-title":"Imaging synucleinopathies","volume":"31","author":"Brooks","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/brain\/awq091","article-title":"In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy","volume":"133","author":"Kikuchi","year":"2010","journal-title":"Brain"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for \u03b1-Synuclein Fibrils","volume":"58","author":"Chu","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0404.1998.tb05958.x","article-title":"Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson\u2019s disease with autonomic failure","volume":"97","author":"Braune","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2019.01.024","article-title":"I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort","volume":"62","author":"Kane","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_168","first-page":"609","article-title":"Lewy bodies in the visceral autonomic nervous system in Parkinson\u2019s disease","volume":"60","author":"Wakabayashi","year":"1993","journal-title":"Adv. Neurol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s004010050693","article-title":"The distribution of Lewy bodies in pure autonomic failure: Autopsy findings and review of the literature","volume":"94","author":"Hague","year":"1997","journal-title":"Acta Neuropathol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000113469","article-title":"Neuropathology of autonomic nervous system in Parkinson\u2019s disease","volume":"38","author":"Wakabayashi","year":"1997","journal-title":"Eur. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2020.10.016","article-title":"Comparison of 123I-MIBG scintigraphy and phosphorylated \u03b1-synuclein skin deposits in synucleinopathies","volume":"81","author":"Giannoccaro","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Yoshita, M., Arai, H., Arai, T., Asada, T., Fujishiro, H., Hanyu, H., Iizuka, O., Iseki, E., Kashihara, K., and Kosaka, K. (2015). Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: A multicenter study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120540"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00401-005-0995-7","article-title":"Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease","volume":"109","author":"Orimo","year":"2005","journal-title":"Acta Neuropathol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/brain\/awm302","article-title":"Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson\u2019s disease","volume":"131","author":"Orimo","year":"2008","journal-title":"Brain"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00401-006-0160-y","article-title":"Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy","volume":"113","author":"Orimo","year":"2007","journal-title":"Acta Neuropathol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/jnnp.71.5.583","article-title":"A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer\u2019s-type and dementia with Lewy bodies","volume":"71","author":"Yoshita","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.055","article-title":"CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"1251","author":"Tokuda","year":"2009","journal-title":"Brain Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00259-015-3146-y","article-title":"Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer\u2019s disease","volume":"43","author":"Shimizu","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jnnp-2017-317398","article-title":"I-MIBG myocardial scintigraphy for the diagnosis of DLB: A multicentre 3-year follow-up study","volume":"89","author":"Komatsu","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/mds.23659","article-title":"Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders","volume":"26","author":"King","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1212\/01.wnl.0000435553.67953.81","article-title":"Myocardial scintigraphy may predict the conversion to probable dementia with Lewy bodies","volume":"81","author":"Oda","year":"2013","journal-title":"Neurology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12149-017-1166-3","article-title":"Correlation between clinical symptoms and striatal DAT uptake in patients with DLB","volume":"31","author":"Shimizu","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov. Disord."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","article-title":"The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism","volume":"28","author":"Booij","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.parkreldis.2006.10.009","article-title":"SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson\u2019s disease","volume":"13","author":"Ashkan","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1471-4159.2009.05904.x","article-title":"Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson\u2019s: An in vivo imaging study","volume":"109","author":"Sossi","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.neurobiolaging.2008.11.009","article-title":"Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD","volume":"31","author":"Novellino","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/jnnp-2012-302577","article-title":"Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT","volume":"83","author":"Morgan","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jnnp.73.2.134","article-title":"Differentiation of dementia with Lewy bodies from Alzheimer\u2019s disease using a dopaminergic presynaptic ligand","volume":"73","author":"Walker","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archneur.61.6.919","article-title":"Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies","volume":"61","author":"Colloby","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1552-6569.2012.00774.x","article-title":"Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: Complementary or alternative techniques?","volume":"24","author":"Treglia","year":"2014","journal-title":"J. Neuroimaging"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ana.24717","article-title":"(123) I-2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study","volume":"80","author":"Tiraboschi","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12149-020-01464-9","article-title":"A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index","volume":"34","author":"Sakamoto","year":"2020","journal-title":"Ann. Nucl. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.parkreldis.2013.05.010","article-title":"Neuropathology of dementia in a large cohort of patients with Parkinson\u2019s disease","volume":"19","author":"Horvath","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","article-title":"Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia","volume":"69","author":"Kotzbauer","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.53.9.2003","article-title":"Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies","volume":"53","author":"Growdon","year":"1999","journal-title":"Neurology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-2009-1227","article-title":"The neuropathology of older persons with and without dementia from community versus clinic cohorts","volume":"18","author":"Schneider","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00401-011-0852-9","article-title":"Neuropathology underlying clinical variability in patients with synucleinopathies","volume":"122","author":"Halliday","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.parkreldis.2014.02.012","article-title":"Concomitant pathologies among a spectrum of parkinsonian disorders","volume":"20","author":"Dugger","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/nan.12308","article-title":"Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum","volume":"42","author":"Sierra","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","article-title":"\u03b2-Amyloid PET and neuropathology in dementia with Lewy bodies","volume":"94","author":"Kantarci","year":"2020","journal-title":"Neurology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.neurobiolaging.2014.07.005","article-title":"Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies","volume":"36","author":"Nedelska","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181bacf9e","article-title":"Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies","volume":"73","author":"Nelson","year":"2009","journal-title":"Neurology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/brain\/aww193","article-title":"Amyloid-\u03b2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies","volume":"139","author":"Sarro","year":"2016","journal-title":"Brain"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13195-017-0272-8","article-title":"Long-term cognitive outcome of Alzheimer\u2019s disease and dementia with Lewy bodies: Dual disease is worse","volume":"9","author":"Blanc","year":"2017","journal-title":"Alzheimers Res. Ther"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jagp.2013.03.001","article-title":"Amyloid PET Imaging in Lewy body disorders","volume":"23","author":"Donaghy","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mds.25286","article-title":"\u03b2-Amyloid in Lewy body disease is related to Alzheimer\u2019s disease-like atrophy","volume":"28","author":"Shimada","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_211","unstructured":"Irwin, D.J., and Hurtig, H.I. (2018). The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J. Alzheimers Dis. Park., 8."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2018.09.004","article-title":"Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies","volume":"73","author":"Mak","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e1916439","DOI":"10.1001\/jamanetworkopen.2019.16439","article-title":"Association of Longitudinal \u03b2-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia","volume":"2","author":"Nedelska","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neurobiolaging.2010.12.015","article-title":"Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia","volume":"33","author":"Burton","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"e3257","DOI":"10.1212\/WNL.0000000000010943","article-title":"\u03b2-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies","volume":"95","author":"Ferreira","year":"2020","journal-title":"Neurology"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/brain\/awn298","article-title":"Medial temporal lobe atrophy on MRI differentiates Alzheimer\u2019s disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis","volume":"132","author":"Burton","year":"2009","journal-title":"Brain"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neurobiolaging.2020.08.003","article-title":"Multimodal in vivo and postmortem assessments of tau in Lewy body disorders","volume":"96","author":"Coughlin","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mds.27252","article-title":"Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases","volume":"33","author":"Lee","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1038\/s41598-018-23041-x","article-title":"F-AV-1451 in Parkinson\u2019s Disease with and without dementia and in Dementia with Lewy Bodies","volume":"8","author":"Smith","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and \u03b2-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000441421","article-title":"PET Radioligands Reveal the Basis of Dementia in Parkinson\u2019s Disease and Dementia with Lewy Bodies","volume":"16","author":"Gomperts","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neurobiolaging.2020.11.006","article-title":"Imaging tau burden in dementia with Lewy bodies using","volume":"101","author":"Mak","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.nicl.2020.102333","article-title":"The combined effect of amyloid-\u03b2 and tau biomarkers on brain atrophy in dementia with Lewy bodies","volume":"27","author":"Abdelnour","year":"2020","journal-title":"Neuroimage Clin."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000065889.42856.F2","article-title":"Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies","volume":"60","author":"Merdes","year":"2003","journal-title":"Neurology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00002093-200101000-00005","article-title":"Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: Effect of coexisting Alzheimer-type lesion load","volume":"15","author":"Hachinski","year":"2001","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0000000000001204","article-title":"Clinicians\u2019 ability to diagnose dementia with Lewy bodies is not affected by \u03b2-amyloid load","volume":"84","author":"Tiraboschi","year":"2015","journal-title":"Neurology"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000354670","article-title":"The significance of \u03b1-synuclein, amyloid-\u03b2 and tau pathologies in Parkinson\u2019s disease progression and related dementia","volume":"13","author":"Compta","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/01.wnl.0000435299.57153.f0","article-title":"MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies","volume":"81","author":"Murray","year":"2013","journal-title":"Neurology"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"111180","DOI":"10.1016\/j.pscychresns.2020.111180","article-title":"Structural imaging in dementia with Lewy bodies: The potential of multivariate data analysis","volume":"306","author":"Ferreira","year":"2020","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/brain\/awl388","article-title":"Focal atrophy in dementia with Lewy bodies on MRI: A distinct pattern from Alzheimer\u2019s disease","volume":"130","author":"Whitwell","year":"2007","journal-title":"Brain"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1097\/RLU.0000000000000547","article-title":"Brain PET in the diagnosis of Alzheimer\u2019s disease","volume":"39","author":"Marcus","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Mosconi, L. (2013). Glucose metabolism in normal aging and Alzheimer\u2019s disease: Methodological and physiological considerations for PET studies. Clin. Transl. Imaging, 1.","DOI":"10.1007\/s40336-013-0026-y"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ana.1133","article-title":"Alzheimer\u2019s disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation","volume":"50","author":"Minoshima","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/WNL.56.5.643","article-title":"Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD","volume":"56","author":"Lobotesis","year":"2001","journal-title":"Neurology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/exnr.2000.7342","article-title":"Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies","volume":"162","author":"Higuchi","year":"2000","journal-title":"Exp. Neurol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"fcaa040","DOI":"10.1093\/braincomms\/fcaa040","article-title":"F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies","volume":"2","author":"Lesnick","year":"2020","journal-title":"Brain Commun."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12149-016-1076-9","article-title":"Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies","volume":"30","author":"Iizuka","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-018-8892-x","article-title":"Neuroimaging in Lewy body dementia","volume":"266","author":"Yousaf","year":"2019","journal-title":"J. Neurol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.25453","article-title":"Metabolic patterns across core features in dementia with lewy bodies","volume":"85","author":"Morbelli","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40478-019-0754-y","article-title":"Intersection of pathological tau and microglia at the synapse","volume":"7","author":"Vogels","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"102200","DOI":"10.1016\/j.nicl.2020.102200","article-title":"Correlation of microglial activation with white matter changes in dementia with Lewy bodies","volume":"25","author":"Nicastro","year":"2020","journal-title":"Neuroimage Clin."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/brain\/awy265","article-title":"Early microglial activation and peripheral inflammation in dementia with Lewy bodies","volume":"141","author":"Surendranathan","year":"2018","journal-title":"Brain"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","article-title":"Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson\u2019s Disease and Dementia with Lewy Bodies","volume":"56","author":"Moors","year":"2019","journal-title":"Mol. Neurobiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/8\/3960\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:34:17Z","timestamp":1760366057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/8\/3960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":245,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijms22083960"],"URL":"https:\/\/doi.org\/10.3390\/ijms22083960","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]}}}